A cash position of more than €20 million at the end of 2022, which provides the Company financial visibility until the end of the first half of 2024; A decisive year on the clinical front
The last patient included in the study has completed the final protocol follow-up visit. The first results of the study will be released before the end of the first half of 2023, after the
Regulatory News: Valbiotis (FR0013254851 ALVAL, PEA SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic
TOTUM•854 protects human cells of the vascular wall, particularly against inflammation and oxidative stress, which is key to preventing worsening of high blood pressure. TOTUM•854 also reduces
A decisive year in clinical terms with results expected in the first half of 2023 from the international Phase II/III REVERSE-IT study on TOTUM•63, a plant-based active substance that has already